BioCryst Pharmaceuticals, Inc.
BCRX
$7.40
$0.182.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 56.59% | 61.18% | 83.17% | 33.66% | 13.71% |
| Total Depreciation and Amortization | 26.91% | -25.95% | -21.38% | -24.44% | 34.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.77% | -2.91% | -53.33% | -9.56% | -43.20% |
| Change in Net Operating Assets | -162.60% | 43.62% | -175.38% | -75.44% | 253.94% |
| Cash from Operations | 41.55% | 141.44% | 92.73% | -12.99% | 62.61% |
| Capital Expenditure | -21.84% | 94.02% | 66.81% | -46.88% | -5.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 166.16% | -64.54% | 87.65% | 127.11% | -135.91% |
| Cash from Investing | 162.50% | -63.28% | 87.13% | 126.85% | -136.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 69.44% | -- | 99.83% | -- | -- |
| Issuance of Common Stock | -- | 40.62% | -85.88% | -66.67% | -96.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -41.99% | 0.38% | 94.28% | -- | -- |
| Cash from Financing | -26.73% | 4.00% | -106.70% | -120.64% | -175.57% |
| Foreign Exchange rate Adjustments | -349.81% | 236.36% | 54.89% | -254.17% | 57.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.13% | 301.26% | 32.74% | 82.41% | -169.16% |